No Data
No Data
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200
Looking Into Ascendis Pharma's Recent Short Interest
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $220
BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany